e-learning
resources
London 2016
Monday, 05.09.2016
Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients
Nkolaj Burinsky (Gomel, Belarus), Vasily Bondarenko, Irina Buynevich, Andrey Holyavkin, Svetlana Goponyako, Nkolaj Burinsky
Source:
International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Session:
Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Session type:
Thematic Poster
Number:
2762
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Nkolaj Burinsky (Gomel, Belarus), Vasily Bondarenko, Irina Buynevich, Andrey Holyavkin, Svetlana Goponyako, Nkolaj Burinsky. Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients. Eur Respir J 2016; 48: Suppl. 60, 2762
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Salivary SLPI and disease severity in bronchiectasis
Risk score of drug-induced liver injury among new tuberculosis patients
PG19 Heart-lung interaction
Related content which might interest you:
Burden of the primary drug resistance of Mycobacterium tuberculosis in HIV-positive patients
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Primary drug resistance in HIV/TB patients
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
Monitoring of drug resistance of TB mycobacteria in new pulmonary TB patients
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT)
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Nonspecific microflora in patients associated with pulmonary multidrug-resistant tuberculosis
Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology
Year: 2015
Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction
Source: Eur Respir Rev 2009; 18: 295-299
Year: 2009
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Year: 2020
Primary drug resistance against mycobacterium tuberculosis in a high burden country
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006
Effect of diabetes mellitus on the Time of mycobacterial clearance from sputum during the treatment of multi-drugs resistant tuberculosis
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2
Year: 2014
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Extrapulmonary tuberculosis in HIV infected patients admitted to the hospital
Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Year: 2016
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Concomitant MDR-TB and candidiasis
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept